Corporate Strategy – Senior Analyst
Immix Biopharma, Inc. (NADSAQ:IMMX)
Remote/Flexible | Los Angeles, CA
Job Description
Immix Biopharma, Inc. (NADSAQ:IMMX)
Corporate Strategy – Senior Analyst
Location: Los Angeles, CA / Hybrid
Full time position
How You Will Contribute
- Responsible for corporate, investor and board presentations
- Responsible for financial and operating models
- Existing Pipeline – Using literature and commercial database research, participate in determining development strategy for existing pipeline
- New Pipeline – Conduct literature and commercial database research to evaluate opportunities to expand pipeline of human therapeutics
Skills and Experience We Look For
Prior healthcare investment banking and/or equity research internship, or work experience (~1-2 years) preferred
Education: BS/BA, or MD/PhD/PharmD/science degree
Our 3 Core Values
- Intelligence
- Integrity
- Initiative
Rewards at Immix
Compensation commensurate with experience. Health insurance and 401k included.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis and short duration of cytokine release syndrome (CRS), supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.